IE840198L - Therapeutic use of nafazatrom - Google Patents

Therapeutic use of nafazatrom

Info

Publication number
IE840198L
IE840198L IE840198A IE19884A IE840198L IE 840198 L IE840198 L IE 840198L IE 840198 A IE840198 A IE 840198A IE 19884 A IE19884 A IE 19884A IE 840198 L IE840198 L IE 840198L
Authority
IE
Ireland
Prior art keywords
nafazatrom
therapeutic use
relates
myocardial
antiischaemic
Prior art date
Application number
IE840198A
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IE840198L publication Critical patent/IE840198L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of 3-methyl-1-[2-(2-naphthyloxy)ethyl]-2-pyrazolin-5-one ("nafazatrom") for the prevention and treatment of myocardial infarcts after myocardial ischaemias and of cardiac dysrhythmias. The invention also relates to antiarrhythmic and antiischaemic pharmaceutical compositions which contain a therapeutically effective amount of nafazatrom. [DE3302811A1]
IE840198A 1983-01-28 1984-01-27 Therapeutic use of nafazatrom IE840198L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833302811 DE3302811A1 (en) 1983-01-28 1983-01-28 Use of nafazatrom in the therapy of cardiac dysrhythmias and myocardial ischaemias, pharmaceutical compositions for this purpose and process for the preparation thereof

Publications (1)

Publication Number Publication Date
IE840198L true IE840198L (en) 1984-07-28

Family

ID=6189416

Family Applications (1)

Application Number Title Priority Date Filing Date
IE840198A IE840198L (en) 1983-01-28 1984-01-27 Therapeutic use of nafazatrom

Country Status (5)

Country Link
JP (1) JPS59141517A (en)
KR (1) KR840007356A (en)
DE (1) DE3302811A1 (en)
IE (1) IE840198L (en)
ZA (1) ZA84637B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35801E (en) * 1985-05-20 1998-05-19 Mitsubishi Chemical Corporation Prophylactic and therapeutic composition for circulatory disorders and method of treatment
WO2005012255A1 (en) * 2003-08-01 2005-02-10 Mitsubishi Pharma Corporation Remedy for inflammatory joint diseases

Also Published As

Publication number Publication date
ZA84637B (en) 1984-09-26
DE3302811A1 (en) 1984-08-02
KR840007356A (en) 1984-12-07
JPS59141517A (en) 1984-08-14

Similar Documents

Publication Publication Date Title
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
CA2289717A1 (en) Novel therapy for constipation
GB2143734B (en) Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
HU892559D0 (en) Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient
PT81007A (en) Process for the preparation of analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives and of pharmaceutical compositions containing the same
AU5159490A (en) Composition and method for administration of pharmaceutically active substances
CA2004239A1 (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
NZ229891A (en) Pharmaceutical composition for the prevention of sexually transmitted diseases
HU895444D0 (en) Process for the preparation of ophthalmic pharmaceutical composition
EP0185210A3 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
GB2256588B8 (en) Preparation for transdermal administration of procaterol
IT1206876B (en) EXTENDED PHARMACEUTICAL COMPOSITIONS RELATED FORMS OF DOSAGE AND PROCEDURE FOR THEIR PREPARATION
AU1950388A (en) Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
CA2301706A1 (en) Use of phanquinone for the treatment of alzheimer's disease
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
GB2162748B (en) Medicinal composition for the treatment or prevention of acne by oral administration
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
IE840198L (en) Therapeutic use of nafazatrom
MX9709453A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form.
HU895948D0 (en) Process for the preparation of dipeptidecarbamide derivatives having inhibition of renine and pharmaceutical compositions thereof
PT80961A (en) Process for the preparation of new pharmaceutical compounds containing mixtures of 4,9-dihydro-4-(1-methyl-4-piperydilene)-10h-benzoý4,5¨-cycloheptaý1,2-b¨thyophene-10-one and antiasthmati c xantines as active ingredient
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
IE890275L (en) Pharmaceutical composition for 4-aroylimidazol-2-ones